Product Description
Fospropofol (FP), also known as GPI15715 or Aquavan, is a new molecular entity with sedative-hypnotic properties, to be administered intravenously and proposed for the indication of sedation in adult patients undergoing diagnostic or therapeutic procedures. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487287/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Anesthesia Related|Bradycardia|Hypotension|Tremor|Other|Pain Unspecified
Phase 3: Carpal Tunnel Syndrome|Pain Unspecified|Bunion|Shoulder Pain|Nasal Polyposis|Pain, Referred
Phase 2: Pain Unspecified|Hypotension|Coronary Artery Disease|Myocardial Ischemia|Other
Phase 1: Pregnancy Outcomes|Drug Hypersensitivity|Anesthesia Related
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400094950 | N/A |
Not yet recruiting |
Unknown |
2027-12-31 |
|
| ChiCTR2400092104 | N/A |
Not yet recruiting |
Anesthesia Related |
2027-10-15 |
|
| ChiCTR2400093011 | N/A |
Not yet recruiting |
Resistant Hypertension|Stroke|Bradycardia|Hypotension|Paresthesia|Tachycardia |
2027-08-31 |
|
| ChiCTR2400085355 | N/A |
Not yet recruiting |
Hepatic Insufficiency |
2027-06-10 |